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ABSTRACT 
Background: Female reproduction is controlled by hormones in a timed and well-coordinated 
manner by the hypothalamus- pituitary - ovarian axis. In response to the ovarian hormones such 
as estrogen, and progesterone, endometrium, the inner lining of the uterus, undergoes repeated 
cycles of tissue growth, differentiation, tissue shedding and remodelling. However, 
dysregulation of those hormones, may generally cause uncontrolled cell proliferation, 
alteration of its invasive, migratory or angiogenic characteristics, leading to the displacement 
of endometrial tissues either outside of uterine cavity, for instance on ovary forming ovarian 
endometriosis; or inwardly into the myometrium causing adenomyosis. Several 
epidemiological studies as well as histological evidences have shown an increased risk of 
developing ovarian cancer among women with endometriosis known as endometriosis 
associated ovarian cancers (EAOC). Similarly, the risk of ovarian cancer is increased among 
carriers of BRCA1 or BRCA2 germline mutations due to error-prone DNA repair mechanisms.  
Aim: We aimed to investigate on early molecular alterations associated with cancer 
development among women with ovarian endometriosis. In addition, treatment or preventive 
strategies for reducing disease symptoms were explored among women with ovarian 
endometriosis, BRCA1 or BRCA2 mutations and adenomyosis, respectively.  
Methods and Results: Study I, we explored if there was a molecular link between 
endometriosis and ovarian cancer development, by analysing multipotent stem/stromal cells 
and tissues of endometrium and endometrioma among women with ovarian endometriosis. We 
investigated for intra-patient heterogeneity within stem- and cancer- cell- pathways using 
targeted PCR array as well as validated for their tumour initiating characteristics. We observed 
that a subgroup of women with endometriosis (4/30 endometrioma) exhibited dysregulation in 
estrogen receptor expression, upregulation of molecules related to epithelial-mesenchymal 
transition pathway such as KIT, HIF2a and E-cadherin as well as downregulation of tumour 
suppressor genes PTEN and ARID1A, thus supporting a link between above molecular changes 
and potential risk of EAOC. 
Study II, we investigated the molecular regulation of Syndecan-1 (SDC-1) and -4 (SDC-4) upon 
induced activation of TGF-b signalling in another cohort of ovarian endometrioma, to 
understand their interactions in the pathophysiology of endometriosis and potential EAOCs. 
Similar to Study I, we also identified molecular heterogeneity with aberrant activation of TGF-
b signalling as well as confirmed their anomalous behaviour using 3D spheroid and invasion 
assays in vitro. Interestingly, the above invasive phenotype could be altered by transient gene 
knockdown of either SDC-1 or SDC-4 during active TGF-b signalling. Moreover, we showed 
that the presence of high levels of TGF-b ligands control endometriotic cell proliferation and 
reduce its 3D-spheroid invasive potential in vitro. Thus, inhibition of SDCs among subjects 
with aberrant TGF-b signalling could be suggested as a potential treatment strategy to reduce 
inherent risk towards EAOC. 
In Study III, we examined the molecular action of selective progesterone receptor modulator, 
mifepristone among women with BRCA1 or BRCA2 mutations. Through in vitro studies, we 
confirmed the anti-proliferative action of mifepristone with inherent levels of progesterone 
among above cohort of BRCA1 or BRCA2 women, thus providing as an alternative preventive 
approach to avoid/delay the use of salpingo-oophorectomy in reducing ovarian cancer risk. 
In Study IV, we demonstrated the mechanism of action for bromocriptine in the first known 
human clinical trial for the management of adenomyosis. Bromocriptine provided a prolactin 
mediated potent growth inhibition, reduced heavy menstrual bleeding as well as exhibited 
reversal of fibrosis, thus could be further explored for reversing the pathogenesis of 
adenomyosis. 
Conclusion: To summarize, this thesis has demonstrated important molecular links underlying 
endometriosis and risk of EAOC. Also, this work has shown the possibilities for early detection 
and potential treatment strategies to reduce disease symptoms and/or inherent cancer risk. 
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1 INTRODUCTION 
1.1 THE ENDOMETRIUM AND THE UTERINE CYCLE 
The inner lining of the uterus, known as the endometrium, has drawn increasing research 
attention in recent years due to its distinct role in women’s health and disease. It provides a 
cycle-dependent environment for the implantation of the blastocyst into the uterus to support 
foetal development (Guyton and Hall 2006). In women of reproductive age, the endometrium 
undergoes more than 400 cycles of well-coordinated events involving growth and 
differentiation as well as subsequent tissue shedding and remodelling, as depicted in Fig. 1. 
Histologically, the endometrium comprises two distinct layers: the upper functionalis layer and 
the lower basalis layer. The functionalis layer comprises the luminal and glandular epithelium, 
surrounded by loose stroma. It regenerates to a thickness of about 4–10 mm at the follicular (or 
proliferative) phase due to a rise in estrogen (E) levels. The basalis layer is richly supplied with 
spiral arteries that have tubular glands and dense stroma (Guyton and Hall 2006). It has been 
reported that the amazing regenerating potential of the endometrium is due to the existence of 
active stem cells within the basalis layer, which repopulate the denuded functionalis layer 
during every menstrual cycle (Gargett and Masuda 2010; Schwab et al. 2005). 
 
Fig. 1 Schematic diagram on different phases in uterine cycle  
Endometrium undergoes a repetitive uterine cycles of tissue regeneration, differentiation, shedding and 
remodelling. E promote endometrial regeneration during follicular phase while P cause differentiation 
and prepares endometrium for implantation during luteal phase. In absence of successful implantation, 
menstrual phase occurs resulting in tissue shedding and remodelling. This image is reused with 
permission from Servier medical art, licenced by Creative Commons Licence 4.0.  
In response to the surge in luteinising hormone (LH) from the pituitary gland, there is a shift 
from the follicular to the luteal (secretory) phase. The LH surge triggers ovulation from the 
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dominant ovarian follicle, which releases an oocyte. Consequently, the empty ovarian follicle 
develops into a hormone-secreting body called the corpus luteum, the role of which is to secrete 
and release progesterone (P). The rise in P levels alternates with a fall in E levels in the 
endometrial functionalis layer, priming it to a secretory decidualised phenotype. The 
endometrium becomes receptive during the mid-luteal phase (6-8 days after ovulation) known 
as the ‘window of implantation’, wherein it allows an embryo to implant. The implantation of 
a human embryo involves sequential events such as apposition, attachment and invasion of 
embryonic trophoblast cells through the uterine luminal epithelial cells. This process involves 
an exchange between the endometrium and the embryo of many molecules belonging to the 
family of cytokines, growth factors and hormones. Glands and blood vessels further grow in 
size; vascular spaces between them become interconnected to form the placenta, which supplies 
oxygen and nutrition to the developing foetus. If there is no fertilised oocyte or blastocyst 
implantation is unsuccessful, there is a rapid fall in P levels. This triggers a cascade of events 
involving constriction of blood vessels, necrosis and desquamation of the endometrial 
functionalis layer, leading to the onset of menstruation. The functionalis layer is shed from the 
uterine cavity during menstruation, leaving the basalis layer intact. (Guyton and Hall 2006; 
Padykula et al. 1984; Jabbour et al. 2006). 
1.2 BENIGN GYNECOLOGICAL DISORDERS  
Women’s reproductive health may be hampered by several gynaecological conditions that can 
place a heavy burden on quality of life, health and wellbeing. Although most benign disorders 
can be treated, a lack of knowledge about their specific symptoms or risk factors may prevent 
women from seeking help at the early stage of the disease. This drives the need for better 
understanding of symptoms and aetiologies for early diagnosis as well as the provision of 
suitable diagnostic, prophylactic and/or treatment measures. Benign gynaecological disorders 
can be broadly categorised into three groups: menstrual disorders, pelvic inflammatory disease 
and benign tumours/cysts.  
(i) Menstrual disorders include amenorrhoea (no menstruation, which may also be a desired 
consequence of treatment), menorrhagia (abnormal bleeding at irregular intervals) and 
heavy menstrual bleeding (HMB, heavy but regular). Other symptoms related to benign 
gynaecological disorders may include dysmenorrhea (painful menstruation), vaginal 
discharge and infertility. Both menorrhagia and HMB can lead to anaemia and severe iron 
deficiency, which result in chronic symptoms such as fatigue, poor wound healing and risk 
of infections (Black and Fraser 2012). Treatment may involve the use of hormonal 
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contraceptives, which might help in reducing excessive or irregular bleeding and 
dysmenorrhea. 
(ii) Pelvic inflammatory disease (PID) is an acute microbial infection primarily caused by the 
disruption of the mucosal lining of the endocervical wall, which provides the means for 
potential pathogens to enter into the upper genital tract. As a consequence, these infections 
may spread to any of the pelvic organs such as the endometrium (endometritis), ovary 
(oophoritis) or uterine wall (myometritis) (Boyle and Torrealday 2008). PID typically 
appears as an indurated and oedematous uterus, with the presence of purulent material, 
ovarian abscess or tenderness, severe abdominal pain during motion/intercourse, HMB and 
vaginal discharge and fever. Oral or parenteral antibiotic regimens and sometimes surgery 
may be used for the treatment of PID and tubal-ovarian abscess (Wiesenfeld and Sweet 
1993). 
(iii) Benign tumours or cysts are formed as cellular outgrowth due to hormonal dysregulation 
(for instance, aberrant estrogen signalling) within the uterus or ovary. They proliferate 
slowly and rarely become cancerous (Boyle and Torrealday 2008). The most common types 
are uterine polyps and fibroids, which are formed in the endometrium or myometrium, 
respectively. On the other hand, a benign cyst can be formed on the ovary due to either an 
unruptured persistent follicle or corpus luteum (functional ovary cyst) or as a consequence 
of retrograde shedding of ectopic endometrial lesions on to the ovary (endometriosis or 
endometriotic cyst (endometrioma)).  
In the context of this thesis, I will focus on two benign gynaecological conditions originating 
in the endometrium, namely (i) endometriosis and (ii) adenomyosis. 
1.3 ENDOMETRIOSIS 
Endometriosis is an estrogen-dependent, chronic inflammatory gynaecological disorder, 
characterised by the presence of endometrial-like tissue outside the uterine cavity that forms 
ectopic lesions or cysts. These lesions and cysts can be found in a wide variety of locations in 
the pelvis; however, they are most frequently found on the ovary, forming endometrioma or 
endometriotic cysts. Sometimes these lesions can penetrate the surface of the peritoneum, 
forming either superficial or deep infiltrating endometriosis. On rare occasion, they may be 
found on other distant anatomical sites such as the bladder, the kidneys, the lungs and even the 
brain (Starzinski-Powitz et al. 2001; Zhao et al. 2015; Pritts and Taylor 2003). Most women 
suffering from endometriosis experience symptoms such as dysmenorrhoea (painful 
menstruation), dyspareunia (painful intercourse), pelvic pain and infertility (Vigano et al. 
2004); there are a few asymptomatic (no symptoms) cases as well. Moreover, the risk of 
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endometriosis increases with reproductive health issues related to menstruation such as shorter 
cycle length, longer duration of menstrual flow and reduced parity. Conversely, the risk of 
endometriosis is increased with alcohol (Parazzini et al. 2013) and coffee consumption (Saha 
et al. 2017) and is decreased with other lifestyle factors such as exercise (Eskenazi and Warner 
1997). 
1.3.1 Prevalence of endometriosis 
The exact prevalence of endometriosis is unknown since the clinical presentation can vary from 
asymptomatic and unexplained infertility to severe symptoms such as dysmenorrhoea and 
chronic pain. The prevalence has been estimated to be around 2%–10% among women of 
reproductive age and about 50–60% of women with either chronic pain or infertility or both 
(Eskenazi and Warner 1997; Goldstein et al. 1980; Meuleman et al. 2009). Moreover, 
endometriosis has a substantial effect on the psychological and social wellbeing of affected 
women and imposes a huge economic burden both on individuals and on society. For instance, 
in the United States, the economic burden has been estimated to be about 12,419 US dollars 
per woman among endometriosis patients (Simoens et al. 2012). In addition, a delay of 6.7 
years has been projected between the onset of symptoms and diagnosis as well as around 10.7 
hours lost per week per woman affected, in terms of productivity due to chronic disease 
symptoms (Rogers et al. 2013).  
1.3.2 Diagnosis of endometriosis 
There are no validated, non-invasive biomarkers for endometriosis. Currently, diagnosis is 
made through laparoscopic surgery and subsequently verified by histological or pathological 
examination. In addition, transvaginal ultrasound (TVUS) and/or magnetic resonance imaging 
(MRI) can be suggested. The American Society for Reproductive Medicine (ASRM) has put 
forth some guidelines for the diagnosis of endometriosis (American Society for Reproductive 
Medicine: Revised classification of endometriosis 1997), including the presence of 
endometrial-like cells on target tissues, accompanied by specific features such as adhesion of 
lesions on the peritoneal wall or ovarian surface, and cyst diameter as well as the presence of 
thick, chocolate-coloured fluid content within the cyst. Based on the above features, ASRM 
has categorised the severity of endometriosis into several stages: minimal (stage 1), mild (stage 
2), moderate (stage 3) and severe (stage 4).  
1.3.3 Theories on the pathogenesis of endometriosis 
Endometriosis is considered a multi-factorial disease, the aetiology of which is not fully 
understood. Several predisposing factors have been proposed regarding its pathogenesis, which 
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could be explained using the ‘two-stage’ theory: initiation and promotion (Parazzini et al. 
2016). The initiation phase of the disease is triggered by factors such as early menarche, 
menstrual cycle length, duration/volume of menstrual flow and parity. Later, promotion factors 
such as immune dysfunction, haeme, free iron-induced oxidative stress, impaired progesterone 
synthesis and apoptosis suppression together with aberrant estrogen secretion, support 
vascularisation and promote growth (Kobayashi et al. 2008). The above hypothetical model for 
endometriotic lesion development is illustrated in Fig. 2.  
 
Fig. 2. Schematic diagram of the role of stem cells in the pathogenesis of ovarian 
endometriosis. Endometrial cells including SCs were shed by retrograde menstruation to peritoneal 
cavity, where they get adhered, implanted and establish endometriotic lesions. Due to immunological, 
genetic and microenvironmental factors, some of the endometriotic cells might gain mutations or gene 
alterations causing altered cellular phenotype. This picture was originally self-drawn, now modified and 
reprinted from Paper-I (Ponandai-Srinivasan et al. 2018). Permission to reuse was provided by Rights 
Link Copyright clearance centre. 
Two important theories will be discussed in relation to the studies involved in this thesis.  
A. Retrograde menstruation theory 
Samson’s retrograde menstruation was the oldest and most accepted theory for the 
pathogenesis of endometriosis. According to this theory, as a consequence of occasional 
retrograde menstrual flow, endometrial tissue was shed into the peritoneal cavity and later 
adhered to the surface of the peritoneum or ovaries, forming ectopic endometrial lesions 
(Sampson 1927). Experimental evidence from non-human primates showed that endometriosis 
could possibly be induced by inoculating autologous menstrual products into the peritoneal 
cavity (D'Hooghe et al. 1994). In addition, the lesions developed from these models were 
histologically and clinically similar to the endometriotic lesions occurring on the ovary or 
peritoneal sites of humans (D'Hooghe 1997). It was suggested that obstructive menstrual 
disorders such as iatrogenic cervical stenosis (narrowing of the passageway through the cervix) 
Fallopian tube
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Ovarian surface epithelium
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Vagina
Ovary
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???
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or congenital menstrual disorders might also increase the risk of retrograde menstruation 
(Burney and Giudice 2012). However, this theory fails to explain why only 10% of women 
have endometriosis even though retrograde menstruation has been observed among 76–90% of 
women (Sasson and Taylor 2008). Furthermore, it does not explain how endometriotic lesions 
can be localised in the lungs, brain, etc. 
B. Stem cell theory 
The immense regenerative potential of the endometrium during menstrual bleeding and the re-
epithelisation of the endometrium after childbirth or surgical curettage support the theoretical 
existence of stem cells (SC) in the endometrium. Adult SC are undifferentiated cells, which 
have the capacity to self-renew upon external stimuli as well as induce differentiation to attain 
a cell-type-specific phenotype with a designated function (Gargett and Masuda 2010). 
Accordingly, researchers have identified adult SC within a highly regenerative endometrium 
(Meng et al. 2007; Gargett et al. 2016), menstrual fluid, peritoneal fluid (O et al. 2017) and 
endometriotic lesions (Gargett and Chan 2006; Gargett et al. 2014; Silveira et al. 2012). 
Clonogenic cells have been identified that express markers of stemness in a long-term culture 
derived from endometriotic lesions, which supports to their role in the pathogenesis of 
endometriosis (Silveira et al. 2012). Moreover, it has been suggested that hyperperistalsis in 
the uterus is associated with the development of endometriosis (Leyendecker et al. 2004). As 
a consequence of hyperperistalsis, endometrial basalis tissue is shed abnormally by retrograde 
menstruation into the peritoneal cavity; once there, the fragments exhibit increased potential to 
implant and proliferate due to higher E levels as well as estrogen receptor (ER) and 
progesterone receptors (PR). In addition, it has been shown that differentiated stromal 
fibroblasts from women with endometriosis inherit the progesterone resistance and pro-
inflammatory phenotype from their SCs (Barragan et al. 2016). It has further been suggested 
that ectopic endometriotic SCs have more invasive and migratory capacity relative to eutopic 
endometrial SCs, studied using both in vitro (Sundqvist et al. 2012) and in vivo models (Kao 
et al. 2011); angiogenesis has also been stimulated. Experts in the field recently proposed that 
the endometrial SC might be shed during uterine bleeding among neonatal girls and that the 
SC remain quiescent within the peritoneal cavity for several years (Brosens et al. 2013). Later, 
if these quiescent cells get reactivated during adolescence due to the function of ovarian 
hormones, it may also facilitate implantation and establishment of endometriotic lesions 
(Gargett et al. 2014; Puttemans et al. 2016). However, certain SC populations may develop 
somatic mutations and gene deregulations due to prolonged exposure to immunological and 
environmental stress, to attain pre-malignant potential (Gadducci et al. 2014; Gargett et al. 
2014).  
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1.4. ADENOMYOSIS 
Adenomyosis, previously called endometriosis interna, is a common, benign gynaecological 
condition, observed in 19.5% of women in reproductive age (Devlieger et al. 2003; Garcia-
Solares et al. 2018). Women with adenomyosis present non-specific symptoms similar to those 
of endometriosis or uterine fibroids such as abdominal pain, HMB and infertility. At the 
beginning of the nineteenth century, all abdominal disorders involving mucosal invasion were 
considered to be ‘adenomyoma’ (Benagiano et al. 2009) since they share several features in 
terms of symptomology, histology and molecular alterations (Leyendecker et al. 2015). Later, 
Frankl (Frankl 1925) created the word ‘adenomyosis’ to describe the presence of ectopic 
endometrial tissue inside the uterine myometrium (Ferenczy 1998). Two years later, Sampson 
(Sampson 1927) proposed retrograde menstruation theory to describe the mechanism of 
peritoneal endometriosis. However, since Samson’s theory does not explain the mechanism of 
endometrial invasion inside the myometrium, adenomyosis and endometriosis have been 
considered to be two separate conditions ever since (Benagiano and Brosens 2006, 2011). 
Women with adenomyosis usually have early menarche, shorter menstrual cycles, increased 
body mass index, are multiparous, relatively older in age and have a history of induced abortion 
(Parazzini et al. 2009; Templeman et al. 2008). 
1.4.1. Prevalence of adenomyosis 
Several reports have suggested a strong association between endometriosis and adenomyosis. 
Both conditions have been closely linked with molecular changes or abnormalities occurring 
either on the inner portion of the myometrium or at the junctional zone (JZ) between the endo- 
and the myometrium, leading to a highly migratory and invasive eutopic endometrium 
(Benagiano et al. 2014). Adenomyosis has been observed in 34.6% of cases having deep 
infiltrating endometriosis while a reference group without endometriosis had an incidence of 
only 19.4% (Bazot et al. 2004). In another study, 40% of endometriosis cases showed irregular 
JZ, as opposed to 22.5% in the non-endometriosis group. In terms of older women (40–50 
years) undergoing surgery for either adenomyosis or uterine fibroids, 34.1% showed co-
existence of endometriosis (Naphatthalung and Cheewadhanaraks 2012). In addition, there was 
a specific correlation reported between adenomyosis and deep infiltrating endometriosis 
(Gonzales et al. 2012) as well as with a group possessing concomitant endometriosis and 
infertility (Kunz et al. 2005). However, it is important to note that most of the above studies 
included cases of co-existing endometriosis with adenomyosis due to a lack of clear guidelines 
or diagnostic criteria for distinguishing between them. As a result, the reported frequency of 
adenomyosis were higher than the real incidence. 
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1.4.2. Diagnosis of adenomyosis 
Adenomyosis is traditionally diagnosed by histological examination following hysterectomy 
(Morassutto et al. 2016). The pathological examination may present as an enlarged, globular 
uterus with areas of hypertrophic and hyperplastic myometrial smooth muscle, along with the 
presence of dark cysts within the myometrium. Histologically, it is visualised by the 
invagination of endometrial glands and stroma through the JZ into the myometrium, as well as 
adjacent myometrial hyperplasia, which causes globular and cystic enlargements in the 
myometrium (Donnez et al. 2018). With the advent of non-invasive imaging techniques such 
as TVUS and MRI, it is now possible to differentiate features specific to adenomyosis and not 
endometriosis, such as diffuse thickening of the inner myometrium, irregular JZ, the presence 
of localised lesions or an increased JZ-to-outer-myometrial ratio (Levy et al. 2013). Moreover, 
adenomyosis may present in two forms, focal or as a diffused, tumour-like growth. A focal 
lesion, also called adenomyoma, might be observed when a circumscribed nodular formation 
appears on the myometrium, while a diffuse form shows a uniform spreading of endometriotic 
glands and stroma throughout the surface and the depth of the myometrium (Gordts et al. 2018). 
1.4.3. Theories on the pathogenesis of adenomyosis 
Similar to endometriosis, the aetiology and pathogenesis of adenomyosis remains largely 
unknown. Here, I will discuss three important theories, namely: Invagination theory, 
metaplasia theory, and De novo stem cell theory. 
A. Invagination theory 
Invagination theory is the most widely accepted theory for the pathogenesis of adenomyosis. 
It suggests that adenomyosis may occur due to the invagination of endometrial glands from the 
basalis layer of endometrium into a traumatised endometrial-myometrial interface via tissue 
injury and repair (TIAR) mechanism, as depicted in Fig. 3A. Several studies have been 
performed to understand the cause and consequences of this mechanism. First, uterine 
peristalsis cause microtrauma to the JZ; however due to hypoestrogenism, there is an elevated 
oxytocin-mediated uterine peristalsis, which further cause auto-traumatisation and induce 
TIAR mechanism in a repetitive cycle (Leyendecker et al. 2015; Leyendecker et al. 2009). In 
addition, small nerve fibre injury inside the uterus during difficult intrapartum episodes has 
also been suggested as the cause of this disease (Quinn 2011). Studies measuring intrauterine 
sinusoidal pressure waves of varying frequencies during menstruation have suggested that the 
highest level of stress prevails on the endometrial-myometrial interface, which might induce 
molecular alteration; this, in turn, leads to the invasion of endometrial cells from the basal layer 
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(Shaked et al. 2015). It has been claimed that the use of repeated sharp curettage causes 
disruption of the endometrial-myometrial border, thereby increasing the incidence of 
adenomyosis (Curtis et al. 2002; Levgur et al. 2000). 
B. Metaplasia theory 
This theory suggests that metaplastic changes occur on embryonic pluripotent Mullerian 
remnants could potentially establish de novo ectopic endometrial lesions at the intra-
myometrial sites (Garcia-Solares et al. 2018), as shown in Fig. 3B.  
C. Stem cell theory 
According to this theory, repeated tissue injury and microtrauma at the JZ, induces activation 
of stem cells and an alteration in its niche (Vannuccini et al. 2017; Gargett et al. 2016). As a 
consequence, progenitor cells are allowed to differentiate in a retrograde direction by breaching 
the endometrial-myometrial interface and establish de novo adenomyosis lesions, as shown in 
Fig. 3C. It has also been postulated that multipotent cells from bone marrow and other sources 
may form de novo focal lesions inside the myometrium. Even though the invagination theory 
is the most widely accepted, de novo lesions from different sources might be a plausible 
mechanism. Hence, more studies are required to further establish the role of endometrial SC or 
Müllerian remnants in the initiation of this disease.  
 
 
Fig. 3. Theories on the pathogenesis of endometriosis. Adenomyosis are formed due to 
displacement of endometrial-like cells or tissues into uterine myometrium, which might be explained 
by (A) Invagination theory (B) Metaplasia theory (C) stem cell theory (reprinted from (Garcia-Solares 
et al. 2018) and permission for reuse provided by RightsLink Copyright clearance centre). 
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1.5. TREATMENT STRATEGIES FOR ENDOMETRIOSIS/ADENOMYOSIS 
There are no disease-specific treatment options available for either endometriosis or 
adenomyosis. The treatments suggested so far have focused on alleviating the disease 
symptoms such as pelvic pain, abdominal cramps and HMB. Both disorders are estrogen-
dependent, implying that the treatment should be targeted at suppressing excess E production 
and overcoming P resistance (Vercellini et al. 2014), thereby promoting fertility (Tsui et al. 
2014). It is important to note that adenomyosis has not been as extensively researched as 
endometriosis. 
1.5.1. Laparoscopic surgery 
Laparoscopic surgery (LS) is the most common mode of treatment for the management of 
endometriosis. LS is performed to remove visible regions of endometriotic lesions or cysts 
either by using an ablation technique, which involves the destruction of a lesion by burning, or 
an excision technique, which implies cutting the lesion out surgically. A Cochrane review 
suggests that LS is moderately associated with reducing overall pain (odds ratio (OR): 6.58, 
95%; confidence interval (CI): 3.31 to 13.10), improving live birth (OR: 1.94, 95%; CI: 1.20 
to 3.16) and clinical pregnancy rate (OR: 1.89, 95%; CI: 1.25 to 2.86) (Duffy et al. 2014). Thus, 
it is very useful to provide relief for pain symptoms and sub-fertility. It is also important to 
remove active deposits of the ectopic lesions that caused pain symptoms. Unfortunately, 
treatment by LS alone may not be sufficient as these lesions tend to recur in cases of severe 
endometriosis (ASRM II/IV). 
1.5.2. Hormonal contraception 
Combined hormonal contraception (CHC) are widely used to treat women with pain associated 
with endometriosis (Jensen et al. 2018). To be effective, they should be used without a break 
(the so called ‘long cycle treatment’) and can be administered in the form of a pill, a patch or a 
vaginal ring. Continuous administration of CHC significantly reduces bleeding, dysmenorrhea, 
pelvic pain, dyspareunia and postoperative disease recurrence; and improve the overall quality 
of life (Vercellini et al. 2014; Grandi et al. 2019). The disadvantages of such treatment include 
contraindications to estrogen such as the increased risk of venous thromboembolism (Ferrero 
et al. 2010).  
Treatment with progestins results in dose-dependent effects on follicular development and 
ovulation; as well as cervical mucus. They also act on all organs with PR, including the 
endometrium. Progestins promote decidualisation and atrophy of the endometrium and 
endometrial implants. Progestins in various forms reduce vaginal bleeding and provide 
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resolution from pain symptoms associated with endometriosis (Brown et al. 2012). The 
levonorgestrel-releasing intrauterine system (52 mg LNG-IUS) is a safe, highly effective and 
accepted reversible, long term contraceptive method as well as an effective treatment for 
uterine disorders such as endometriosis or adenomyosis related pain and HMB (Gemzell-
Danielsson et al. 2011). High local concentrations of LNG provided by the IUS in the 
endometrium and to a lesser degree in the myometrium results in decidualisation and 
endometrial atrophy, usually without suppressing ovulation (dose-dependent effect).  
Selective progesterone receptor modulators (SPRM, such as ulipristal acetate, mifepristone, 
and vilaprisan, exert an agonist, antagonist or mixed effect due to their competitive action with 
P on PRs. SPRMs were developed for the treatment of endometriosis and studied for the 
treatment of adenomyosis; they are also available for the short-term treatment of uterine 
fibroids (Whitaker et al. 2017; Schutt et al. 2018; DeManno et al. 2003).  
Other treatment possibilities include aromatase inhibitors (Ferrero et al. 2011) and selective 
estrogen receptor modulators. The latter act as antagonists on ER, thereby inhibiting 
endometrial proliferation and inducing atrophy (Tsui et al. 2014). Also, gonadotropin releasing 
hormone agonists (such as buserelin, goserelin, leuprolide, nafarelin, and triptorelin), are 
effective in inducing amenorrhea and reducing pain. However, hypoestrogenic side effects 
limit their use unless an add-back therapy is given (Tsui et al. 2014). 
1.6. ENDOMETRIOSIS-ASSOCIATED OVARIAN CANCERS (EAOC) 
Endometriosis is generally considered a benign disorder; however, on rare occasion, it may 
exhibit certain characteristics of malignancy such as uncontrolled growth, neo-angiogenesis, 
local invasion and migration (Munksgaard and Blaakaer 2012; Starzinski-Powitz et al. 2001). 
Several epidemiological studies have consistently shown endometriosis carries an increased 
risk for various malignancies (Kok et al. 2015; Munksgaard and Blaakaer 2012); the strongest 
association was observed for ovarian cancer, known as endometriosis-associated ovarian 
cancer (EAOC) (Melin et al. 2006; Lundberg et al. 2019; Saavalainen et al. 2018; Pearce et al. 
2012). A meta-analysis conducted on EAOC estimated that about 80% of reported cases were 
of ovarian origin (Heidemann et al. 2014; Kim et al. 2014) and the remaining 20–25% were 
on extragonadal sites such as a peritoneal cavity, lower pelvis, gastrointestinal tract, abdominal 
wall, umbilicus, recto-vaginal septum, colon, pleura and others (Heaps et al. 1990; Irvin et al. 
1998; Brooks and Wheeler 1977). 
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1.6.1. Prevalence of EAOC 
A recent population-based cohort study showed an increased incidence of EAOC among 
women diagnosed with both endometriosis and infertility (adjusted Hazard risk (aHR) ratio: 
2.19, 95%CI 1.70 – 2.82) compared to women diagnosed with only endometriosis (aHR: 1.77, 
95%CI 1.53 – 2.05) or infertility (aHR: 1.53, 95%CI 1.36 – 1.72) (Lundberg et al. 2019). 
Moreover, endometriosis shows an increased risk, specifically towards the endometrioid 
(standardised incidence ratio (SIR): 2.26) and clear cell (SIR: 3.95) subtypes of ovarian cancers 
(Brinton et al. 2005; Saavalainen et al. 2018; Pearce et al. 2012). Moreover, Saavalainen et al. 
(2018) performed a sub-analysis based on the type of endometriosis (ovarian, peritoneal and 
deep infiltrating) and the independent risk of each endometriosis type towards different types 
of genital cancers (ovary, cervix, endometrial, etc.) (Saavalainen et al. 2018). Interestingly, 
there was a strong association reported between incidence of ovarian cancer among women 
with ovarian endometriosis (SIR: 2.56 (1.98–3.27)), specifically for the endometrioid (SIR: 
4.72 (2.75–7.56)) and clear cell (SIR: 10.1 (5.5-16.9)) sub–types. However, women with both 
peritoneal endometriosis (SIR: 1.32 (0.99–1.72)) and deep infiltrating endometriosis (SIR: 1.41 
(0.29–4.1)) showed no increase in the overall risk for ovarian cancer. In addition, the risk of 
endometrial cancer was not altered in any type of endometriosis. 
1.6.2. Histological markers of EAOC 
Several chronological events have been documented that support a strong link between 
endometriosis and the development of ovarian cancer. Based on microscopic observations, 
Sampson (1925) proposed a set of criteria for the diagnosis of ovarian cancer in women with 
endometriosis; these criteria were as follows: (i) clear evidence of endometriosis close to 
tumour; (ii) demonstration of cancer arising within or from endometrioma, but not from 
anywhere else; and (iii) histological identification of tissue resembling endometrial stroma 
surrounding characteristic epithelial glands. is decreased with lifestyle factors such as exercise 
(Eskenazi and Warner 1997). Later, Scott (1953) elucidated an additional criterion: evaluation 
of the morphological changes that continuously occur within the epithelium during 
transformation from benign to malignant in endometriosis (Scott 1953). Currently, the above 
four histological criteria are used for diagnosing the transition from benign to malignant 
conversion in ovarian endometriosis (Tanase et al. 2013). 
Several histological pieces of evidence suggest that EAOC may originate from atypical 
endometriosis of the ovary (Fukunaga et al. 1997; Czernobilsky and Morris 1979). Atypical 
endometriosis has been characterised as being similar to hyperplasia of the endometrial glands 
with cytological atypia (Clement 2007; Seidman 1996) and has been detected in 80% of EAOC 
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cases (Fukunaga et al. 1997; Worley et al. 2013). It possesses some unique features, such as 
eosinophilic cytoplasm, large hyperchromatic or pale nuclei with moderately marked 
pleomorphism, an increased nuclear-to-cytoplasmic ratio, cellular crowding and stratification 
or tufting. It has also been suggested that other factors, such as genetic, immunological, 
environmental (including microenvironmental) and cytokines play a key role in the malignant 
transformation of endometriosis to EAOC (Worley et al. 2013; Varma et al. 2004). 
1.6.3. Molecular markers of EAOC 
In the past two decades, numerous studies have consistently shown that EAOC may arise from 
genetic alterations that occur within an endometrioma due to the altered peritoneal 
microenvironment. One possible explanation might be the accumulation of haeme, free iron 
and reactive oxygen species from menstrual reflux, which may induce oxidative stress and 
develop mutations in key genes. Yamaguchi et al. (2008) showed that the concentration of free 
iron was significantly higher in endometriotic cysts compared to non-endometriotic cysts. In 
addition, endometriotic cyst fluid also expressed high levels of reactive oxygen species such as 
8-hydroxy-deoxyguanosine similar to the levels observed in carcinomas (Yamaguchi et al. 
2008) and their higher levels were associated with poor prognosis in epithelial ovarian cancer 
(Pylvas et al. 2011). Furthermore, an impaired immune response may also cause chronic 
inflammation and macrophage or aberrant cytokine activation, which would trigger mutations 
within endometrioma (Gazvani and Templeton 2002).  
Alternatively, there might be inherent mutations in eutopic endometrial cells among susceptible 
subjects due to family history or impaired hormonal activity. They may also add more 
mutations as a consequence of local inflammation or altered niche within endometriotic cysts 
during retrograde flow. Some of the common somatic mutations and genomic aberrations 
reported during malignant transformation of EAOC include: silencing of the key tumour 
suppressor genes TP53 (Sainz de la Cuesta et al. 2004; Akahane et al. 2007), PTEN (Govatati 
et al. 2014) and ARID1A (Wiegand et al. 2010); oncogene activation of KRAS (Amemiya et al. 
2004; Stewart et al. 2012), PIK3CA and CTNNB1 (McConechy et al. 2014) and 
downregulation of BCL2 (Nezhat et al. 2002; Akahane et al. 2007). A study analysing deep 
infiltrating endometriotic lesions with no risk of EAOC demonstrated several mutations in 
cancer-driver genes, such as ARID1A and PI3KCA (Anglesio et al. 2017), that were commonly 
mutated in both clear cell ovarian carcinomas and concurrent endometriotic lesions (Anglesio 
et al. 2015). Moreover, EAOC cases also show loss of BAF250a expression, a protein encoded 
by ARID1A, especially within areas of contiguous endometriosis or atypical endometriosis 
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surrounding the tumour; this implies their expression has a role in the early stages of malignant 
transformation of endometriosis (Stamp et al. 2016). 
Furthermore, the DNA mismatch repair genes hMLH1 or hMLH2 were also inactivated by 
hypermethylation within endometriotic tissue (Esteller et al. 1999). In some cases, aneuploidy 
in the advanced stages of endometriosis was reported, particularly along chromosome 17, on 
which tumour suppressor gene TP53 resides (Kosugi et al. 1999). Moreover, microsatellite 
analysis performed with EAOC patients showed a loss of heterozygosity among both cancerous 
and benign endometriotic lesions from the same patient, indicating endometriosis might be a 
clonal precursor to a subtype of ovarian cancer (Sato et al. 2000). This also implies that the 
molecular mechanisms that accompany the changes in EAOC might be different from ovarian 
cancer developed without a history of endometriosis. Hence, there is a need for a better 
understanding of its pathogenic mechanisms in order to develop specific prophylactic measures 
and avoid potential tumour growth among EAOC patients. 
1.7. BRCA1 OR BRCA 2 MUTATIONS AND OVARIAN CANCER RISK 
The breast cancer gene 1 (BRCA1) and gene 2 (BRCA2), are tumour suppressor genes that play 
a key role in monitoring DNA damage response and repair of DNA double-strand breaks by 
homologous recombination. However, cells that bear mutations in BRCA1 or BRCA2 repair 
DNA lesions via an alternative error-prone mechanism that leads to genomic instability and 
increased risk of breast and ovarian cancers (Stoppa-Lyonnet 2016).  
1.7.1. Prevalence of BRCA1 or BRCA2 mutations 
Hereditary mutations constitute around 15–20% of all cases of ovarian cancers; mutations on 
BRCA1 or BRCA2 are the major contributors (65–85%) within that category (Norquist et al. 
2016). Pathogenic BRCA1 or BRCA2 mutations have been observed in 20% of high grade 
serous cancers, and 8% with clear and endometrioid histological subtypes of ovarian cancers 
(Alsop et al. 2012). Moreover, the lifetime risk for developing breast cancer due to BRCA1 or 
BRCA2 mutations has been estimated to be around 50–80%. With regard to ovarian cancer, the 
lifetime risk has been individually estimated to be around 30–60% and 10–25% due to BRCA1 
and BRCA2 mutations (Kuchenbaecker et al. 2017). In addition, it has been observed that the 
age at diagnosis for ovarian cancer with BRCA1 or BRCA2 mutations is older than that of breast 
cancer; for instance, the mean age for BRCA1 and BRCA2 mutation is around 40–60 years and 
50–70 years respectively (Finch et al. 2014). In addition, both these mutations increase the risk 
of other cancers such as BRCA1 for fallopian tube cancer and primary peritoneal cancer, and 
pancreatic cancer, prostate and breast cancer among BRCA2 mutation carriers. 
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In a general, unselected ovarian carcinoma cohort, 19% of cases were observed to have 
pathogenic and less/likely pathogenic (P/LP) germline variants of the BRCA1 or BRCA2 
mutations (Maistro et al. 2016). Another cross-sectional study that screened for the prevalence 
of P/LP variants showed five times more individuals with P/LP variants by next-generation 
sequencing than previously detected based on personal or family history (Manickam et al. 
2018); this indicates the need for genetic screening to identify BRCA1 or BRCA2 mutation 
carriers with potential cancer risk. 
1.7.2. Theories on the pathogenesis of BRCA1 or BRCA2 mutations and 
cancer development 
The association between BRCA1 or BRCA2 germline mutations and its potential cancer risk 
can be explained based on Knudson’s ‘two-hit’ hypothesis (Knudson 1971). According to the 
hypothesis, each tumour suppressor gene must undergo two hits (mutations) in its allelic pair 
in order to develop cancer (Knudson et al. 1975). With hereditary cancers, one of the hits is a 
germline mutation observed in all somatic cells, while the occurrence of the second hit is a 
deletion of a wild-type allele within the somatic cells of the target tissue. Accordingly, it has 
been shown that women with the BRCA1 mutation bear one inherited mutant allele and another 
wild-type BRCA1 allele. However, in most cancers, the wild-type allele is deleted, leaving no 
functional BRCA1 gene (Merajver et al. 1995). In this model, the inheritance pattern is 
autosomal-dominant, meaning that the mutant BRCA1 or BRCA2 allele was inherited from the 
previous generation. With respect to molecular expression, however, the BRCA1 or BRCA2 
gene exhibits a recessive pattern since both the alleles need to be downregulated or inactivated 
to form a tumour (Rosen 2013).  
Moreover, the relationship between BRCA1 or BRCA2 and TP53 also plays a critical role in 
the pathogenesis of breast and ovarian cancers. BRCA1 or BRCA2 interacts with tumour 
suppressor TP53 and regulates DNA damage response as well as cell-cycle checkpoint 
activation, especially through CHK1, which blocks cell-cycle progression in the Gap 2/Mitosis 
(G2/M) phase. With BRCA1 or BRCA2 deficiency, it has been suggested that TP53 and p21 
are activated to regulate genomic instability, resulting in cell-cycle arrest or senescence. As 
expected, the incidence of TP53 mutations is higher among BRCA1 mutated cancers (>80%) 
compared to sporadic cancers (25%) (Holstege et al. 2009). Jiang et. al. (2011) reported that 
TP53 mediates the nuclear transport of BRCA1 by disrupting the BRCA1-BARD complex; 
hence, TP53 mutations among BRCA1 mutated carriers might amplify their chromosomal 
abnormalities due to repeated error-prone DNA damage response, which leads to increased 
incidence of breast or ovarian cancer.  
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1.8.  STRATEGIES FOR REDUCING OVARIAN CANCER RISK AMONG HIGH-
RISK POPULATIONS 
Women with high risk for ovarian cancer were suggested with various risk-reducing strategies, 
which might vary in their effectiveness and potential side effects. Here, I will be discussing the 
important prevention strategies, namely prophylactic surgery and chemoprevention. 
1.8.1. Prophylactic surgery  
Risk reducing Salpingo-oophorectomy (RRSO) shows decreased risk of breast and ovarian 
cancer (Domchek et al. 2010; Rebbeck et al. 2009) as well as improved overall survival (Eleje 
et al. 2018) among women with BRCA1 or BRCA2 mutations. However, RRSO were 
accompanied by adverse effects such as infertility, sexual dysfunction, premature menopause 
and increased morbidity; in addition, they had a negative impact on body image and quality of 
life (Domchek et al. 2010; Madalinska et al. 2005; Rocca et al. 2006). Alternatively, reduced 
cancer risk with limited side effects was reported with the use of prophylactic salpingectomy 
with ovarian retention (Carcangiu et al. 2006; Finch et al. 2006) and tubal ligation (sterilisation) 
(Kjaer et al. 2004; Sieh et al. 2013). In addition, it has been suggested that combination 
strategies such as hysterectomy plus RRSO (Hazard ratio (HR): 0.06) provide better protection 
compared to the use of either tubal ligation (HR: 0.72) or hysterectomy (HR: 0.79). 
1.8.2. Chemoprevention 
It has been suggested that CHCs reduce the risk of epithelial ovarian cancers among both the 
general (EAOC) and the high-risk population (BRCA1 or BRCA2 carriers) and that their 
protective effect is improved with long-term use (Havrilesky et al. 2013; McLaughlin et al. 
2007; Iodice et al. 2010). SPRMs such as mifepristone (MIFE) also show promising results in 
experimental settings for reducing or delaying the use of RRSO or inherent cancer risk. For 
instance, mifepristone (MIFE) has been shown to prevent mammary tumorigenesis in an 
animal model of the BRCA1 mutation (Poole et al. 2006). In addition, clinical studies 
examining a low dose of MIFE exhibited a favourable, anti-proliferative effect on breast tissue 
in premenopausal women (Engman et al. 2008). On other hand, the use of non-steroidal anti-
inflammatory drugs and aspirin show diverse effects in several epidemiological studies. 
1.9. ENDOMETRIAL STEM CELLS 
The human endometrium is a highly regenerative organ which regrows from a thickness of 1–
2 mm just after menstrual shedding to its full thickness of more than 14 mm during the secretory 
phase of the menstrual cycle. Considering the immense regeneration potential, it has been 
suggested that endometrial tissue might contain a population of SC with a capacity to self-
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renew and produce differentiated cells indefinitely, in order to restore the endometrium after 
every menstrual cycle. 
1.9.1. Historical overview of endometrial SC  
Prianishnikov was the first to postulate the existence of SC (Prianishnikov 1978). Over a 
decade ago, a rare clonogenic population was identified within pure epithelial and stromal cells 
that has the capacity to form colonies and differentiate into mesenchymal lineages (Chan et al. 
2004). Subsequently, a putative cell population, known as label-retaining cells were identified, 
that can retain bromodeoxyuridine after their incorporation into a mouse endometrium (Chan 
and Gargett 2006). Consequently, another form of clonogenic cells known as endometrial side 
populations (SP) were identified, which efficiently efflux Hoechst dye (Cervello et al. 2011). 
These SP cells were able to exhibit self-renewal and multi-lineage differentiation capacities in 
vitro as well as undergo tissue reconstitution in vivo. Concurrently, Taylor (2004) reported that 
the HLA-mismatched bone-marrow derived stem cells from donors were successfully 
engrafted into the recipient endometrium, suggesting that the endometrium could be 
regenerated from non-uterine stem cells (Taylor 2004). Subsequently, the putative stem cells 
were suggested to be of hematopoietic origin and postulated their key role in endometrial 
regeneration and disease pathologies (Du and Taylor 2007).  
1.9.2. Endometrial SC in regeneration and diseases 
Prianishnikov suggested a model on hierarchical hormone responsiveness for the regeneration 
of endometrial cells during each uterine cycle (Prianishnikov 1978). According to the model, 
endometrial SCs are located deep inside the epithelium of the basalis endometrium and may 
not be subjected to any destruction during menstrual bleeding. These SC are a very small pool 
of hormone-independent cells (Ferenczy 1976) and their proliferation is chiefly regulated by 
microenvironmental factors as a consequence of tissue injury. Upon SC division, first-
generation progenitor cells (E2-cells) are formed, which express ER in response to raising E2 
levels in the uterine cavity. Concurrently, the second-generation daughter cells (E2-P cells), 
unlike E2-cells, are formed during the later stage of the proliferative phase and become 
responsive to both P and E2 by expressing both ER and PR. Subsequently, E2-P cells further 
divide in response to higher P levels in the secretory phase; they later undergo terminally 
differentiated P cells with decidualised cellular phenotype. During menstruation, only P-cells 
residing in the functionalis layer are denuded from the endometrial surface, leaving their 
predecessors intact. The above model is illustrated in Fig. 4. 
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Fig. 4. Postulated model on the involvement of stem cells in endometrial regeneration 
Stem cells and its progenitors are influenced by estrodiol (E2) and progesterone (P) resulting in the 
formation and distribution of various cell types at different stages of uterine cycle. Abbreviations (ST-
cell=stem cell; E2-cell=ER+ progenitors; E2P-cell= both ER+ and PR+ progenitors; P-cell= PR+ 
differentiated cells). The image is reused from (Tempest, Maclean, et al. 2018) and permission for reuse 
provided by Creative Commons 4.0. 
However, due to constant and prolonged stimulation of E2, which alternates with insufficient 
P levels in the uterus, the equilibrium of the above processes may be disturbed; this may have 
potential implications in proliferative uterine disorders such as endometriosis or adenomyosis. 
Also, it was proposed that the functionalis endometrium in women with endometriosis 
possesses a high percentage of ‘basalis-like cells’ that are subsequently shed via retrograde 
menstruation and contribute to the initiation of ectopic endometriotic implants (Leyendecker 
et al. 2002). The above theory remains unproven since it is not possible to differentiate between 
cells originating in the basalis layer and those originating in the functionalis layer. 
1.9.3. Markers for identifying endometrial SC  
It has been suggested that putative SC from the endometrium are formed from heterogeneous 
cell clusters, including stromal, epithelial and endothelial progenitors, as depicted in Fig. 5. It 
has been hypothesised that epithelial progenitors in the basal compartment initiate the 
regeneration to form differentiated luminal and glandular epithelial cells. However, it has been 
challenging to identify endometrial epithelial SC due to a lack of specific markers as well as 
techniques to culture and maintain epithelial cells for longer duration in vitro. As of now, 
epithelial SC activity has been demonstrated for markers SSEA-1 (Hapangama et al. 2019; 
Valentijn et al. 2013), SOX9 (Tempest, Maclean, et al. 2018; Hapangama et al. 2019), N-
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cadherin (Nguyen et al. 2017), Musachi-1 (Gotte et al. 2008; Tempest, Baker, et al. 2018), 
LGR5 (Tempest, Baker, et al. 2018) and in a small proportion of previously characterised SP 
cells (Cervello et al. 2011; Masuda et al. 2010). In addition, it has been suggested that 
characterised SP cells are predominantly of endothelial origin (Cervello et al. 2011; Masuda et 
al. 2010). On the other hand, stem cells of stromal/mesenchymal origin are usually fibroblast-
like and reside within the perivascular space along with loose stroma in the basalis layer of the 
endometrium. Some suggested markers with confirmed stem cell properties are as follows: 
CD146+, PDGF-Rβ+ (Schwab and Gargett 2007), W5C5/SUSD2 (Masuda et al. 2012), CD44, 
CD29, CD73, CD90 and CD105 (Meng et al. 2007; Gargett et al. 2009; Dominici et al. 2006).  
 
Fig.5. Schematic diagram on the postulated location of endometrial progenitors in the 
human endometrium. Putative stem cells were supposed to be formed in basalis region of 
endometrium and composed of stromal (CD140b+CD146+ /W5C5/ SP), epithelial (SSEA-1+ SOX9+ 
/ SOX9 / N-cadherin) and endothelial (SP) cell clusters. The image is reprinted from (Gargett et al. 
2016) and permission for reuse provided by Rights Link Copyright clearance centre. 
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2. AIM AND OBJECTIVES 
This study aimed to investigate early molecular alterations associated with the development of 
EAOC among women with ovarian endometriosis. In addition, we wanted to explore the 
possibilities for early detection and potential treatment strategies to reduce disease symptoms 
and/or inherent cancer risk among women with ovarian endometriosis, BRCA1 or BRCA2 
mutations and adenomyosis.  
The specific objectives of the thesis were as follows: 
Ø To understand whether there is a molecular link between endometriosis and ovarian 
cancer by exploring the gene deregulations within the endometrium and endometrioma 
of women with ovarian endometriosis. 
Ø To explore the role and regulation of syndecan -1 (SDC-1) and -4 (SDC-4) in 
Transforming growth factor-β (TGF-β) signalling on endometriotic stem/stromal cells 
in vitro, in order to understand interactions and involvement in the pathophysiology of 
endometriosis-associated cancer. 
Ø To evaluate the mechanism of action for the selective progesterone receptor 
modulator, mifepristone, on BRCA1 or BRCA2 mutated ovarian stem/stromal cells in 
vitro, as a preventive option to reduce inherent ovarian cancer risk. 
Ø To decipher the mechanism of action for the dopamine agonist, bromocriptine, on the 
endometrium of women with adenomyosis, as a prophylactic treatment option to 
reduce heavy menstrual bleeding.  
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3. METHODOLOGICAL CONSIDERATIONS 
3.1. PATIENT COHORTS AND STUDY DESIGN 
Characteristics Study I Study II Study III Study IV 
Tissue biopsies of 
interest 
Endometrial (En)-
healthy (H), Eutopic (P) 
and Endometrioma 
(Endo) biopsies 
Endometrioma 
biopsies 
BRCA1 or BRCA2 
mutated ovarian 
punch biopsies  
Endometrial 
biopsies before 
and after 
bromocriptine 
treatment 
Sample size (n) 
 
H-En-14, P-En-37, 
Endo-30 15 9 8 
Inclusion criteria 
Surgically verified endometriosis (ASRM 
III-IV) with no indications of cancer 
Positivefor BRCA1 
or BRCA2 mutation 
Diffuse 
adenomyosis 
Volunteers—fertile age, 
regular menstruation, 
parity, clinically 
examined for the 
absence of hormonal 
disorders Not applicable 
Exclusion criteria 
Subjects had not received any hormonal 
medications for at least three months 
before surgery. Median age <45 years No ovarian cancer 
Subjects 
diagnosed for 
endometriosis by 
TVUS and MRI 
Median age 
(range) in years 
H-En ≤40;  
P-En & Endo:33 (23-43)  34 (23-43)  42 (37-65) 45 (39-50)  
BMI (Kg/m2) 22.3 ± 3.5 unknown 23.2 ± 2.5 24.4 ± 3.6 
Menopausal 
status Premenopausal 
Postmenopausal-4; 
Premenopausal- 5 Premenopausal 
Menstrual cycle 
phase 
H-En: secretory phase; 
P-En-proliferative (19), 
secretory (17); Endo 
(proliferative–19, 
secretory–11) 
Proliferative–
4, secretory–2, 
others- 
unknown Unknown 
Proliferative 
phase 
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3.2. ETHICAL CONSIDERATIONS 
All studies were performed in accordance with the ethical permits approved by the institutional 
ethical review committee at Karolinska Institutet, Sweden (Study I and II (2008/1566-31/3 and 
2016/95-31/4), III (2010/661-31/1), IV (2013/2060-31/12)), University of Tartu, Estonia (Study I) 
and the Mayo Clinic, USA (Study IV). Study IV was approved by the Medical products agency 
as well as registered at clinicaltrials.gov (NCT01821001) and Eudract.ema.europa.eu 
(EudraCT 2013-004409-14). Informed consent was obtained from all cases and controls, prior 
to their inclusion in the study. 
3.3. ISOLATION OF CD90+CD73+CD105+STEM/STROMAL CELLS  
CD90+CD73+CD105+ stem/stromal cells (SC+) were isolated from healthy volunteers (Study 
I), eutopic endometrium (Study I), and ectopic endometrioma (Paper I and II) from women 
with endometriosis, as well as 4 mm ovarian punch biopsies in women with BRCA1 or BRCA2 
mutations (Paper III). We opted for the most commonly used mesenchymal markers, CD90, 
CD73 and CD105, suggested by the International Society for Cell Therapy (Dominici et al. 
2006), the expression patterns of which have been reported to remain unaltered during 
prolonged culturing conditions (Jones et al. 2010; Pittenger et al. 1999). Alternatively, other 
markers have been suggested in the literature, such as CD146, PDGFRb (Schwab and Gargett 
2007) and SUSD2/W5C5 (Masuda et al. 2012), the expression patterns of which are altered 
during prolonged culturing conditions in vitro due to low oxygen tension (Tormin et al. 2011) 
or spontaneous differentiation (Yang et al. 2018). We restricted our analysis to sorted SC+ until 
passage 6 and adopted physiologically relevant culturing conditions such as 3D-spheroid 
cultures. This approach enabled us to avoid discrepancies with colony formation and 
multipotent differentiation capacities, reported previously on later-passaged cells (Digirolamo 
et al. 1999; Pittenger et al. 1999).  
3.4. TARGETED PCR ARRAY AND CLUSTERING ANALYSIS 
We used a targeted gene array with a customised panel of markers, previously reported for its 
role in premalignancy in endometriosis and/or EAOC. The list of genes is summarised in Table 
S1 (Paper I). This approach was preferred over whole transcriptome analysis as the expression 
differences observed among cancer-associated markers might be small and hence could be 
masked by other known genes involved in disease pathogenesis or hormone-dependent 
regulation.  
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Initially, we screened for a panel of 42 preselected genes on cultured SC+ and validated the 
observations with only 25 out of 42 genes on frozen tissues of both eutopic endometrium and 
ectopic cyst (Table S1 and marked with *). As a form of method development, we also used 
the above panel of genes in paraformaldehyde-fixed ectopic cyst tissues (Paper II). 
Furthermore, intra-patient heterogeneity based on the gene expression patterns from the above 
panel of genes was explored using hierarchical clustering on heatmap and principle component 
analysis (PCA). Using both these methods, we were able to identify samples with higher gene 
expression variability or molecular heterogeneity, which was later validated using functional 
analysis such as 3D spheroid suspension and invasion cultures. 
3.5. TREATMENT DOSES 
For Study II, we explored the consequences of high levels of TGF-β ligands secreted in 
peritoneal fluid in the context of pathogenesis of endometriosis. However, the reported TGF-β 
levels in the literature were ambiguous, ranging among 2 ng/ml, 250 ng/ml and 900ng/ml in 
women with infertility, endometriosis at stage I–II and endometriosis at stage II–IV, 
respectively (Pizzo et al. 2002). In contrast, only a smaller difference of approximately 10 
ng/ml vs. 1 ng/ml was observed by (Oosterlynck et al. 1994) between women having 
endometriosis vs. control women with no benign pathology. Hence, we selected a wide range 
of rhTGF-β doses such as 2 ng/ml, 10 ng/ml or 250 ng/ml and an equivalent dose of 
transforming growth factor receptor beta-I/II (TGFRBI/II) inhibitor Ly2109761 to either 
activate or downregulate TGF-β signalling in vitro.  
In Study III, a MIFE dose for in vitro treatment was selected based on the effect of dose 
dependency for proliferation and apoptosis markers. However, the optimal dose of 10 µM 
MIFE was equivalent to an in vivo oral dose of 200 mg MIFE, which is the (single)dose used 
for emergency contraceptives. Moreover, P concentration was five times greater than MIFE, in 
order to balance the difference between their binding affinity with PR.  
In Study IV, the in vivo effects of bromocriptine on the endometrium were explored by 
providing 5 mg of vaginal bromocriptine treatment every day for six months to women with 
adenomyosis. The above dose was selected based on previous literature for reducing disease 
symptoms associated with hyperprolactinemia (Kletzky and Vermesh 1989). 
3.6. SPHEROID CULTURES 
Three-dimensional spheroid suspension and invasion cultures were used to provide a 
physiologically relevant condition for sorted SC+ where they exhibit their proliferation and 
 26 
invasion capacity in three-dimensional space. Spheroid cultures allow cells with higher colony-
forming capacity to form only multicellular spheroids during serum-starved special growth 
conditions; cells in the later stages of differentiation exhibit low colony-forming capacity 
(Kunz-Schughart et al. 1998; Lin and Chang 2008). Spheroid suspension cultures were 
previously used to enrich the population with cancer-initiating characteristics, known as cancer 
stem cells (CSC) (Dey et al. 2009; Kunz-Schughart et al. 1998). Hence, we used a specifically 
designed spheroid enrichment media comprising DMEM/F12 with growth factors such as 
FGFb, EGF, B27, Insulin-Transferrin-selenium and allowed the SC+ to form suspension 
3Dspheroids by growing them in ultra-low attachment plates/flasks. The above culturing 
system was able to evaluate whether the aberrant gene expression within certain samples 
correlates with the expression profile of CSC markers. In addition, we used a 3D-spheroid 
invasion assay to allow SC+ from eutopic and ectopic endometrial cells to migrate within the 
extracellular matrix in the presence of chemotherapeutic agents such as paclitaxel to evaluate 
chemo-resistance in vitro (Paper I). Furthermore, we challenged endometriotic SC+ with TGF-
β and/or transient gene silencing of SDC-1 or SDC-4 and evaluated for their invasive behaviour 
using an in vitro 3D-invasion assay, 3D spheroid formation assays and transcriptomic analysis. 
3.7. TRANSCRIPTOMIC SEQUENCING AND ANALYSIS 
We performed transcriptomic analysis to evaluate differentially expressed (DE) genes from 
invaded 3D-spheroids that were transiently silenced for genes SDC-1 or SDC-4 in combination 
with or without rhTGF-β (Paper III). In addition, transcriptomic profiles were assessed on 
endometrial tissues that were obtained before and after bromocriptine treatment in women with 
adenomyosis (Paper IV). Since it was required to measure transcriptome from a few thousand 
cells, we used a SMART-seq2 protocol for library preparation in both Studies III and IV 
(preparations were made in accordance with (Picelli et al. 2014)); the protocol has the 
sensitivity to detect signals from single cells. However, it is very selective for poly-adenylated 
(poly-A+) RNA; hence, information on poly-A- RNA was not detected in the analysis. 
Furthermore, the above protocol lacks strand specificity of mRNAs, implying that the 
information on copy number variability between differentially regulated genes might be lost. 
The Partek analysis tool (Partek Inc., CA) was used to screen for differentially expressed genes 
and annotate those gene expression patterns towards specific pathways involved in disease 
development. 
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4. RESULTS AND DISCUSSION 
4.1. PAPER I 
In this study, we hypothesised that there might be aberrant activation or silencing of genes 
relevant to pathways in cancer within stem/stromal cells of endometrioma, which may have a 
potential link with the onset/development of EAOC. 
4.1.1. Eutopic and ectopic SC+ did not express ovarian CSC markers 
We evaluated the gene deregulations between endometrium and endometrioma using two 
independent cohorts, namely, the SC+ cohort and the Tissue cohort, which involve sorted 
stem/stromal cells and whole tissues, respectively. We first observed that the sorted SC+ 
samples from both healthy and endometriosis (eutopic endometrium and ectopic 
endometrioma) samples in the SC− cohort exhibited enrichment of the suggested endometrial 
stem/stromal markers (W5C5/SUSD2+ and MCAM/CD146+), expressed significantly high 
levels of pluripotent markers (OCT3/4, SOX2 and NANOG) and successfully differentiated into 
all three mesenchymal lineages (adipocytes, osteocytes and chondrocytes) in comparison with 
negatively sorted SC−, hence providing substantial pieces of evidence for its multipotentiality 
and stem cell phenotype.  
Moreover, we compared the above endometriosis and healthy control groups for expression of 
CSC-associated markers (ALDH1+ (Ginestier et al. 2007; Penumatsa et al. 2010; Silva et al. 
2011), CD133+ (Curley et al. 2009; Kusumbe et al. 2009; Silva et al. 2011) and CD44v6+ (Gun 
et al. 2012; Shi et al. 2013)), which were previously characterised for their aberrant expression 
in ovarian cancer. As expected, CSC markers showed no significant group-wise differences 
between the healthy and patient sample groups, when evaluated for marker expression 
individually or in combination with other markers, using both real-time PCR and flow 
cytometry, respectively.  
4.1.2. A subset of endometriomas aberrantly expressed stem- and cancer- 
related genes 
Interestingly, one endometrioma SC+ (#36) showed an exceptionally aberrant increase in gene 
expression for dedifferentiation markers (SOX2, NANOG), hypoxia-induced oxidative stress 
markers (HIF1α) and higher percentage in co-expression of CD44+CD133+ by flow cytometry; 
it also exhibited increased colocalization of CD44v6 and CD133 with immunofluorescent 
imaging analysis in comparison to all other endometrioma, eutopic as well as healthy 
 28 
endometrial SC+ samples (Paper I, Fig. 3B–D). Furthermore, gene expression datasets from the 
targeted PCR array were analysed for intra-patient heterogeneity using hierarchical heatmap 
clustering and PCA. A few samples of endometrioma (such as patient nos. #36 and #24 in the 
SC cohort as well as E238.3 in the tissue cohort, hereafter referred to as Endo-hi) specifically 
showed higher molecular heterogeneity compared to other endometrioma samples (referred to 
as Endo-lo) such as upregulation of cancer-associated genes (E-cadherin, EPAS1 and KIT) and 
downregulation of tumour suppressor genes (PTEN and ARID1A which were incidentally 
mutated in EAOC cases (Ayhan et al. 2012; Govatati et al. 2014)). Previously, the loss of 
BAF250a expression (the protein encoded by ARID1A) was correlated with the early onset of 
EAOC (Xiao et al. 2012). Considering a lower expression pattern for ARID1A specifically in 
Endo-hi samples, it would be beneficial to measure the encoded BAF250a protein levels on 
such unique samples in the future. Moreover, Endo-hi samples from both cohorts exclusively 
expressed higher levels of the ER-b-to-ER-a ratio (Lazennec 2006; Pujol et al. 1998), 
indicating a molecular shift to compensate for the observed aberrant expression phenotype 
among cancer-driven genes. Incidentally, we also observed high a E-cadherin to N-cadherin 
ratio specifically among Endo-hi tissue (E238.3) compared to the remaining low-expression 
samples in the Tissue cohort.  
4.1.3. An aberrantly expressed endometriotic SC+ exhibited chemo-
resistance  
We were further interested in understanding the physiological relevance of the above 
premalignant phenotype and correlating it with its cancer initiation capacity and chemo-
resistance. Hence, we examined the above samples from the SC+ cohort for its invasion 
potential in the presence and absence of 10 µM paclitaxel treatment using a 3D-spheroid 
invasion system. Paclitaxel, a chemotherapeutic drug, is currently used as a first-line 
chemotherapy regimen for ovarian cancer (Ledermann 2018). As expected, the endometrioma 
SC+ group showed a significant decrease in the in vitro invasion area upon treatment with 10nM 
paclitaxel (1.33 µm2 vs. 2.47 µm2, P<0.05; Fig. 6) compared to no-treatment cells when 
cultured for an extended duration within a 3D-spheroid invasion assay. Interestingly, one of 
the Endo-hi samples (#36) in the paclitaxel-treated group exclusively exhibited higher in vitro 
invasion potential compared to other samples, indicating the possibility of the existence of 
cancer stem-like cells in such rare endometrioma. However, in vivo tumour formation capacity 
needs to be explored before further confirming the existence of CSC in such unique samples. 
From the above findings, we speculate there might be a very rare quiescent population with 
premalignant and reprogrammed characteristics, attributed to cancer initiation for samples such 
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as #36 (and to a lesser extent, #24), which might be clonally expanded upon activation by 
treatment with a high dose of chemotherapy drugs for prolonged periods of culture. Further 
investigation on such rare patient characteristics could potentially result in a better 
understanding of EAOC.  
Fig 6. Functional assessment of chemo sensitivity to paclitaxel treatment among high- and 
low-expression variability samples in an endometriosis SC cohort using in vitro 3D-
spheroid invasion assay. (A) Representative images of 3D spheroids, cultured in an extracellular 
matrix along with invasion media, chemoattractant MCP-1, in the presence or absence of 10 nM 
paclitaxel, and evaluated for its in vitro invasion capacity using 3D-spheroid invasion assay. B) Trend 
curves representing the invasion area of 3D-spheroids in the absence or presence of 10 nM paclitaxel 
treatment (day 0–8), measured using ImageJ software, between patient samples (i) P-EnSC and (ii) 
EndoSC (n=8 both). (C) Scatter plot shows the increase in invasion fold area measured at the end of 10 
nM paclitaxel treatment (day 8) for individual samples within each patient subgroup, normalised against 
respective untreated samples (dotted line = baseline). Symbols ‘*’ P<0.05. 
4.1.4. An aberrantly expressed endometriotic tissue had previous incidence 
of non-gynaecological cancers 
In the Tissue cohort, the E238.3 sample was separated as an outlier (CI>95%) as it showed a 
unique higher variability trend among 22/25 analysed genes. Having identified some unique 
molecular profiles for that patient, we looked into the medical records of patients in the Tissue 
cohort for the risk factors associated with the disease such as stage of endometriosis, infertility, 
recurrent endometriosis, smoking and gynaecological/non-gynaecological comorbidities. 
Surprisingly, we found that patient E238.3 had been diagnosed with stage IV recurrent 
endometriosis at the time of surgery and had a prior history of melanoma. Though it is of a 
non-gynaecological cancer type, there are a few convincing epidemiological and clinical 
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reports on an association between endometriosis and the risk of melanoma (Kvaskoff et al. 
2009; Kvaskoff et al. 2007); however, the molecular link between them is not known. 
4.2. PAPER II 
In this follow-up study, we intended to use the validated panel of molecular markers from Study 
I to identify patient samples with higher molecular heterogeneity and explore a potential 
treatment strategy to reverse their invasive behaviour in vitro.  
4.2.1. A subgroup of endometriomas aberrantly expressed syndecans and 
molecules of TGF-b signalling 
First, we included patient #36 from the previous study as we wanted to correlate whether the 
premalignant characteristics observed in Paper I could be further established with in vitro 
functional analysis. We performed gene expression clustering analysis on a new cohort of 
endometriosis samples (15 endometriotic samples, including sample #36) using 20 genes in a 
targeted PCR array. Two of the 15 samples (patient #36 (included from the previous study) and 
#23, Endo-hi) were clustered outside the ellipse in a PCA plot, implying variability with more 
than 95% CI. Eleven of the 15 samples (Endo-lo) had homogenous gene expression patterns. 
The remaining two samples (#44 and #18) showed a certain level of gene expression 
variability; however, it was non-significant (Fig. 1B Paper II). The two Endo-hi, when 
compared to the remaining samples, showed aberrant expression of molecules involved in 
TGF-β signalling such as TGF-β1, ESR1, CTNNB1, SNAI1 and BMI1. Incidentally, also in 
Paper I, we observed higher mRNA levels of TGF-β1 and molecules of TGF-β signalling 
(BMI1 and CTNNB1) among high variability samples. 
Previous studies have shown that higher TGF-β1 levels were secreted in peritoneal fluid 
(Oosterlynck et al. 1994; Pizzo et al. 2002; Young et al. 2014) and peritoneal and endometriotic 
lesions (Akl et al. 2015; Tamura et al. 1999); they were also associated with increased severity 
of endometriosis (Young et al. 2014; Pizzo et al. 2002; Oosterlynck et al. 1994) as well as an 
increase its metastatic potential in the ovary (Lamouille et al. 2014; Bierie and Moses 2006). 
On a similar note, heparan sulphate proteoglycan coreceptors SDC-1 and SDC-4 (Chelariu-
Raicu et al. 2016) have been reported to be upregulated in endometriotic cells and their 
deregulation was reported in several solid tumours (Akl et al. 2015; Chen et al. 2018). In our 
cohort, we observed higher expression levels of SDC-4 and SDC-1 for Endo-hi compared to 
Endo-lo samples. Thus, by linking both these lines of thought, we explored their interactions 
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in the context of the pathophysiology of endometriosis and the potential risk for developing 
EAOC. 
4.2.2. In vitro activation of TGF-β signalling inhibited endometriotic cell 
growth and invasion  
We showed that activation of TGF-β signalling by treatment with 2 ng/ml rhTGF-β1 reduced 
the in vitro proliferation and invasion potential in endometriotic cell line 12Z as well as patient-
derived endometriotic SC+. Alternatively, treatment with an equivalent dose (0.06 µM) of 
TGFRBI/II inhibitor Ly2109761 displayed increased invasion potential, thus confirming a 
tumour-suppressive role for TGF-β towards the pathogenesis of endometriosis (Paper II, Fig. 
2). However, we did not observe any difference between the selected low (2 ng/ml) or high 
(250 ng/ml) rhTGF-β1 doses with respect to the key transcription factor of TGF-β signalling 
(SNAI1), protein levels of pSMAD3 as well as in vitro proliferation or invasion potential of 
endometriotic SC+ spheroids. It might be possible that the above non-significant increase upon 
in vitro rhTGF-β1 treatment might be due to the fact that endometriotic samples recruited for 
this study were already diagnosed with a severe stage of endometriosis (ASRM stage -3 or -4) 
and might therefore be prone to higher TGF-β1 levels in their peritoneal fluid and hence they 
were already primed to a mesenchymal phenotype via epithelial mesenchymal transition 
(EMT). 
4.2.3. A subset of endometriotic SC+ exhibited resistance to TGF-β induced 
growth inhibition 
Activation of TGF-β signalling by rhTGF- β1 on 12Z endometriotic SC+ showed significant 
upregulation of SDC-1 and downregulation of SDC-4 at both the mRNA and protein levels. 
We also observed the reversal of the above effect upon its inhibition with Ly2109761. Similar 
to the above response, patient-derived Endo-hi SC+ (samples #36 and #23) exclusively showed 
upregulation of SDC-1 compared to their respective controls, while no such difference was 
observed with Endo-lo samples. Likewise, Endo-hi samples also exhibited higher invasion 
potential upon activation of TGF-β signalling. Knowing that the aberrant expression of SDC-
1 was reported in several solid tumours (Akl et al. 2015), we hypothesised the invasion 
potential of Endo-hi SC+ might be regulated by high SDC-1 expression and lead to TGF-β 
induced tumour suppression.  
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4.2.4. Transient knockdown of SDC-1 and SDC-4 reversed the premalignant 
characteristics during active TGF-β signalling 
In line with that hypothesis, transient gene knockdown of both SDC-1 and SDC-4 reduced 
downstream targets of TGF- β signalling (SNAI1 and pSMAD3) at both the mRNA and the 
protein levels. We investigated whether reducing the expression of SDC-1 and SDC-4 in the 
presence and the absence of active TGF-β signalling had an impact on premalignant 
characteristics of endometriotic SC+. Interestingly, the resistance towards TGF-β-induced 
tumour suppression, shown previously by Endo-hi SC+ spheroids, was reversed to a significant 
level only upon SDC-1 inhibition. Moreover, transcriptomic signatures from the above invaded 
spheroids (gene silenced for SDC-1 together with activated TGF-β signalling) showed 
downregulation of several cancer-associated growth signalling pathways (Paper II, Table I). 
Thus, we found a direct relationship between SDC-1 levels and TGF-β signalling towards 
regulating premalignant characteristics. Therefore, we postulate that the inhibition of high 
SDC-1 levels in the presence of active inherent TGF-β signalling might have an onco-
protective effect on endometriomas exhibiting high molecular heterogeneity. 
From the findings of Studies, I and II, we speculated on the potential mechanisms of EAOC 
development among women with ovarian endometriosis, in two possible steps. (A) Cells from 
eutopic endometrial SC+ may be activated due to dysregulated endometrial niche signals such 
as aberrant estrogen synthesis and progesterone resistance. Retrograde menstruation occurs as 
a consequence of uterine hyperperistalsis and other risk factors; this disperses the inherently 
active endometrial tissues onto the peritoneal cavity as implants/lesions. Later, aberrant 
estrogen signalling within these lesions stimulates SC+ to express high levels of markers related 
to epithelial mesenchymal transition (EMT) and promotes implantation of lesions on the 
peritoneum, ovary or other sites. (B) Upon exposure to high levels of peritoneal fluid factors 
or insults from chronic inflammation, ectopic endometriotic SC might develop stochastic 
somatic mutations within cancer driver genes; these may later cause dedifferentiation and lead 
to malignant transformation of cells on the ovary.  
4.3. PAPER III 
In this study, we focused on exploring the mechanism by which the SPRM, MIFE, acts on 
healthy ovaries from BRCA1 or BRCA2 mutated carriers. Currently, mastectomy and salpingo-
oophorectomy are considered to be the first line of prophylactic treatment measures to reduce 
the incidence of breast and ovarian/fallopian cancer (Domchek et al. 2010; Kauff et al. 2008; 
Rebbeck et al. 2009). Previously, MIFE has been shown to inhibit cancer growth in vivo and 
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in vitro on ovarian cancer cell lines (Goyeneche et al. 2007). However, its molecular action on 
BRCA1 or BRCA2 mutated healthy ovaries still needs to be explored. Here, we hypothesised 
that MIFE may control cell growth on BRCA1 or BRCA2 mutated ovaries and might thereby 
provide an alternative treatment strategy for reducing or delaying ovarian cancer risk. 
4.3.1. Heterogeneity in PR levels and their clinical impact 
As we know that MIFE binds competitively with PR (Chabbert-Buffet et al. 2005), we explored 
whether the recruited samples possess sufficient levels of PR to have the desired drug action. 
We isolated the previously characterised mesenchymal stem/stromal markers CD90, CD73 and 
CD105 and evaluated for the expression of PR and OCT3/4 between SC+ and SC− from BRCA1 
or BRCA2 mutated ovarian cells. As we expected, SC+ showed significantly higher OCT3/4 
expression compared to SC− while PR showed a non-significant trend, indicating the relevance 
of this study for multipotent stem/stromal cells. Interestingly, five out of nine patients showed 
higher PR expression compared to the remaining samples, and the expression of the latter 
samples was comparatively similar to their respective sorted negative fractions SC− (Fig. 1E). 
The above observation allowed us to question whether the higher PR levels may have a 
potential cancer risk. Hence, we performed a principle component analysis to correlate the 
heterogeneity in PR levels with their respective clinical characteristics. We categorised them 
into high- and low-PR expression subgroups based on the above differences and observed three 
distinctly separate clusters. Cluster 1 had two high-PR expressed samples, B57 and B28, 
marked in blue spots. Cluster 2 had one low-PR and one high-PR expressed sample, B50 and 
B54 respectively, marked in pink and blue spots respectively. Cluster 3 had three low-PR 
expression samples, B53, B45 and B26, marked in pink, and two high PR expression samples, 
B49 and B15, marked in blue. When analysing these cluster distributions with respect to 
contributing clinical factors (Figs. 7A–B), Cluster 1 comprised two high-variability PR patients 
who were previously reported with an incidence of breast cancer and ongoing concomitant 
hormonal medication, such as tamoxifen. Alternatively, Cluster 3, which has predominately 
more low-variability PR samples, had no previous cancer history and was not under any 
hormonal or concomitant medication.  
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Fig. 7. Correlation of PR levels with patients’ clinical characteristics using principle 
component analysis. The graph shows (A) Clustering of BRCA1 or BRCA2 mutated samples. (B) 
corresponding distribution of clinical characteristics. The data was analysed using SIMCA 14 software 
(Sartorious Stedim Biotech) and illustrated using Prism 7 (Graphpad Inc.). 
4.3.2. Anti-proliferative action for MIFE on BRCA1 or BRCA2 mutated ovaries 
To study MIFE’s mechanism of action on BRCA1 or BRCA2 mutated healthy ovaries, we 
challenged those ovarian SC+ with increasing doses of MIFE (0.1, 1, 10, 25 and 100 µM) in 
vitro. We observed a dose-dependent anti-proliferative effect, with reduced expression of 
proliferation marker ki67 and BrdU as well as an increase in doubling time for cell growth. 
However, 10 µM was considered an optimal dose compared to 25 µM, as the latter does exhibit 
activation of BCL2 and a MAPK growth signalling pathway as well as upregulation of tumour 
suppressor gene TP53. Since our cohort already possesses the BRCA1 or BRCA2 mutation that 
induces genomic instability, the suboptimal concentration of MIFE may further disturb the 
growth signalling; thus, TP53 were activated to enforce regulation between survival and 
apoptosis machinery.  
4.3.3. Combined MIFE and P treatment reduced proliferation and p21 
mediated cell cycle arrest 
We performed a combination treatment of MIFE with an agonist of PR and glucocorticoid 
receptor (GCR), namely, P or hydrocortisone (HC), in order to evaluate MIFE’s drug action 
with inherent P levels. In line with our hypothesis, combination treatment with P and MIFE 
showed reduced proliferation compared to combination treatment with MIFE and HC. 
Specifically, the P and MIFE combination treatment lowered the expression of proliferation 
(ki67 and BrdU), increased its doubling time and reducing the expression of tumour suppressor 
genes (TP53 and PTEN). On the other hand, BCL2 was upregulated with MIFE and P 
treatment. It was previously shown that BCL2 regulates pro-apoptotic or anti-apoptotic factors 
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based on its interaction with BAX or BCL-XL respectively (Adams and Cory 2018). 
Interestingly, we neither detected BAX nor cleaved caspase-3 at protein levels. In addition, the 
gene expression for BAX showed no difference for any of the treatments, indicating that MIFE 
in the presence of inherent P expression does not induce apoptosis. This also allowed us to 
speculate as to whether BCL2 in the absence or lower expression of TP53 may induce cell 
survival mechanisms, including a transient state of cell cycle arrest. As observed previously 
with ovarian cancer cell lines (Goyeneche et al. 2007), our data also indicated that the 
combination treatment of MIFE and P on BRCA1 or BRCA2 mutated ovarian cells induced cell 
cycle arrest at the G1/S phase, with upregulation of p21CIP1 and corresponding lower levels of 
CDK2 (a downstream target of p21). In addition, it presented with a higher percentage of pro-
apoptotic cells. Finally, we investigated whether the drug action might cause a permanent cell 
cycle arrest. A kinetic proliferation assay suggested that MIFE induces only a temporary halt 
in growth signalling until the termination of treatment, implying the need for prolonged usage 
of this drug to effectively control tumour growth. The postulated mechanism of action for 
mifepristone from the above observations is presented in Fig. 8. 
 
Fig. 8. Postulated molecular mechanism of action for mifepristone among BRCA1 or 
BRCA2 mutation carriers. MIFE acts as a competitive agonist on either PR or GCR (or sometimes 
both), inducing activation of growth signalling such as MAPK-ERK or PI3K pathway which activate 
mTOR and increases the cellular activity, leading to active cell proliferation. Tumor suppressor gene 
TP53 controls the proliferative activity of cells by regulating cell cycle arrest (mediated by p21) or 
apoptosis (by disrupting BCL2-BAX complexes which promotes caspase 3) upon upregulation of growth 
signalling. This illustration is self-drawn using Adobe Illustrator, with biological arts and shapes 
obtained from Servier medical art, licenced by Creative Commons 4.0). 
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Therefore, we confirm that MIFE treatment in the presence of inherent P levels confers a potent 
anti-proliferative effect via inducing p21 mediated cell cycle arrest. Moreover, an optimal dose 
of MIFE and other SPRMs could possibly be developed as an alternative preventive strategy 
to retard tumour cell growth among women with BRCA1 or BRCA2 mutations. 
4.4. PAPER IV 
In the fourth study, we explored the mechanism of action for bromocriptine, a dopamine 
agonist, as a prophylactic treatment strategy for reducing disease symptoms (such as HMB, 
pelvic pain, etc.) associated with adenomyosis. Adenomyosis, previously known as 
endometriosis interna, was believed to develop when the endometrium ‘invades’ the 
myometrium. Adenomyosis shares several features with other gynaecological disorders (such 
as endometriosis and uterine fibroids), in terms of symptomology, histology and molecular 
alterations (Leyendecker et al. 2015; Lazzeri et al. 2014). Similar to endometriosis, 
adenomyosis also shows increased proliferative and invasive capacity due to increased estrogen 
production, progesterone resistance and impaired cytokine expression.  
The pathogenesis of this disease is unknown; however, animal studies have shown that the 
increased prolactin levels (hyperprolactinemia) are regulated by increased levels of estrogen in 
the uterine cavity (Yamashita et al. 1997; Lupicka et al. 2017) and the degree of prolactin 
(PRL) upregulation is correlated with increased severity of the disease (Mori et al. 1991; 
Lupicka et al. 2017). Bromocriptine is the gold standard for the treatment of 
hyperprolactinemia (Kletzky and Vermesh 1989). Administration of bromocriptine vaginally 
to hyperprolactinaemic women lowered their PRL levels to normal, restored menstrual 
cyclicity and fertility (Ginsburg et al. 1992). Thus, we hypothesised that vaginal administration 
of bromocriptine may reduce the PRL levels as well as their accompanying disease symptoms 
in women with adenomyosis.  
4.4.1. Bromocriptine treatment reversed tissue injury and reduce cell activity 
Adenomyosis tissues were previously shown to undergo repeated tissue injury via the TIAR 
mechanism and healing processes, resulting in TGF-b-induced collagen deposition and 
fibrogenesis (Leyendecker et al. 2009; Liu et al. 2016). Our results indicated that the 
bromocriptine treatment inhibits fibrosis by downregulating molecules of collagen 
biosynthesis compared to non-treated samples. Moreover, mitochondrial genes involved in 
oxidative phosphorylation and active ATP production were downregulated in bromocriptine-
treated samples; this was a reversal of the previous report suggesting increased oxidative 
phosphorylation in women with adenomyosis. Thus, we believe that bromocriptine provides a 
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favourable outcome by overcoming tissue injury and modulating the overall cellular activity 
within the endometrium of women with adenomyosis. 
4.4.2. Patients with good response to bleeding outcomes exhibited low 
expression of proliferation markers 
We correlated the molecular changes induced by bromocriptine treatment with the bleeding 
outcomes, measured using a pictorial blood loss assessment chart (PBLAC). As we expected, 
most of the patients in the cohort had reduced bleeding symptoms; two patients, referred to as 
good responders, performed exceptionally well with a PBLAC reduction score of more than 
50%. We further explored the unique molecular characteristics of those two cases compared to 
the rest of the samples in the cohort. It was surprising to note that the treated samples did not 
show any significant pathway alteration between good responders and the rest of the samples. 
However, when we compared the untreated baseline samples, good responders showed 
downregulation of molecules involved in apoptosis, cell cycle, mismatch repair pathways and 
hedgehog signalling. Specifically, ki67 and BCL2 showed lower expression within those 
pathways. However, the previous report suggested that adenomyosis patients possess a higher 
expression of endometrial BCL2 during the proliferative phase (Jones et al. 1998). Considering 
that the samples obtained in the study were from the proliferative phase, we suggest the 
outcome of the treatment was determined based on its inherent cellular phenotype. Moreover, 
BCL2 negatively regulates the expression of BAX and promotes apoptosis. It was suggested 
that BAX expression is relatively absent among adenomyosis patients with regard to increased 
BCL2 expression (Huang et al. 2003). However, in our cohort, we observed a closer non-
significant trend with upregulation of BAX and downregulation of ki67 for bromocriptine-
treated samples, compared to the paired non-treated samples. 
4.4.3. PRL expression correlated positively with ki67 and BAX 
Previously, it was shown that engraftment of a portion of pituitary gland (which produces high 
levels of prolactin) within mouse uteri upregulates a 2–10-fold increase of prolactin receptor 
(PRL-R) and prolactin (PRL) mRNA levels and is associated with pathogenesis of 
adenomyosis (Yamashita et al. 1997). Correspondingly, bromocriptine was shown to reduce 
hyperprolactinemia (Kletzky and Vermesh 1989). Unfortunately, neither receptor showed any 
significant reduction upon treatment with bromocriptine compared to non-exposed tissues. 
Nevertheless, we found a correlation between PRL-R and PRL in relation to molecules 
regulating cell growth (such as ki67 and BAX). As previously observed, only the baseline 
treatment showed a positive correlation for ki67 and BAX with PRL. On the other hand, no 
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correlation was observed in relation to PRL-R either at baseline or at six months of 
bromocriptine treatment. To confirm whether there was a reduction in PRL secretion levels as 
a consequence of bromocriptine treatment, it might be worth investigating their levels in the 
uterine fluid of women who have undergone the above treatment. In addition, we postulate that 
the bromocriptine induces growth inhibition via a non-PRL-R mediated mechanism, which 
requires further exploration.  
Therefore, we confirm that the vaginal administration of bromocriptine induced potent 
endometrial growth inhibition accompanied by a reversal of tissue injury. In addition, it 
overcame HMB, pelvic pain and other factors related to the pathogenesis of adenomyosis. 
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5. CONCLUSIONS  
To summarise, this thesis work has shown the importance of understanding the early molecular 
alterations associated with malignant transformation in the ovary. This emphasises the need for 
early screening and establishes the possibility of development of some suitable prophylactic or 
preventive measures. Though the incidence of cancer is rare among individuals with 
endometriosis (which are usually benign), it is worth being aware of the possible warning signs 
and available treatment options to reduce any potential risk. 
In Study I, we were able to show that the customised panel of markers was sufficient to 
distinguish molecular heterogeneity among endometriomas. The identified small subgroup 
exhibited aberrant levels of stem- and cancer-cell-related gene signatures (KIT, HIF2a, E-
cadherin) dysregulated ER signalling and downregulation of key tumour suppressor genes 
(PTEN, ARID1A).  
In Study II, functional analysis of another cohort of ovarian endometriosis enabled us to 
confirm that the subgroups of patients with aberrantly expressed biomarkers have anomalous 
behaviour/development, which can be reversed by modulating either SDC-1 or SDC-4 during 
active TGF-b signalling. With regard to the pathogenesis of the disease, we revealed that the 
presence of high levels of TGF-b may have an impact on controlling endometriotic cell growth 
as well as reducing their premalignant potential in vitro.  
In Study III, we could evaluate the tumour-suppressive role of the SPRM, mifepristone, in 
controlling BRCA1 or BRCA2 mutated ovarian cell growth; this may pose an alternative 
treatment for reducing ovarian cancer risk as well as avoid/delay risk-reducing salpingo-
oophorectomy.  
In Study IV, we demonstrated the mechanism of action for bromocriptine in the first human 
clinical trial for the management of adenomyosis. With regard to reduced bleeding symptoms, 
bromocriptine provided PRL-mediated potent growth inhibition, reduced cellular activity and 
reversal of fibrosis demonstrating a potential role in the treatment of adenomyosis.  
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6. STUDY LIMITATIONS 
Studies I and II  
Ø From both the studies, 5/44 (11%) endometrioma samples showed aberrant molecular 
profiles for stem- and cancer-associated genes and support the potential risk of developing 
ovarian cancer. Considering the rare occurrence of EAOC (1–2.5%) among women with 
ovarian endometriosis, the above findings seems to be a bit of an overestimation compared 
to the actual occurrence of cancer. 
Ø We have adopted a targeted panel of preselected genes to identify samples with higher 
molecular heterogeneity among women with ovarian endometriosis. This approach might 
have missed several other differentially regulated genes with its key role in cancer 
development (for instance CXCR4, which was not in our preselected panel of genes, but 
later identified by transcriptomic analysis on 3D-invasion spheroids in Study II). 
Ø We have identified highly altered gene signatures among certain endometriomas in all three 
ovarian endometriosis cohorts, performed certain functional analyses (3D spheroids, 
invasion assays, chemo-resistance, etc.) and correlated their expression patterns with the 
clinical history of patients to speculate on their potential risk of developing EAOC. 
However, we may not be able to confirm whether those identified potential risk cases might 
really develop cancer later in life until a prospective evaluation can be done.  
Ø In Study I, the high expression of CSC-associated makers and chemo-resistance capacity 
were exclusively observed in one endometrioma sample (#36) in the SC cohort. 
Incidentally, the same sample also showed reversal of premalignant characteristics upon 
inhibition of SDC-1 or SDC-4 during active TGF-ß signalling (Paper I). However, the above 
key observation requires further validation using animal studies focussing on the existence 
of CSCs as well as possibilities for reducing their tumour initiating capacity in vivo. 
Study III 
Ø This study involved healthy volunteers with BRCA1 or BRCA2 mutations. However, it 
lacked the appropriate controls such as healthy volunteers with a non-mutated BRCA gene. 
Hence, we were not able to assess whether the observed cell cycle arrest was due to the 
impact of an error-prone DNA-damaged pathway (because of the BRCA1 or BRCA2 
mutations) or the result of a mifepristone-mediated anti-proliferative effect. 
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Ø We included patients with varied clinical characteristics (such as two patients with 
tamoxifen treatment (due to prior incidence of breast cancer), two patients with BRCA2 and 
the remaining five patients with BRCA1 mutations as well as differences in their menopausal 
status), which may have contributed to differential PR expression and exhibited variability 
in their anti-proliferative effect. 
 
Study IV 
Ø The small size of the study population (only eight samples out of 18 recruited patients) were 
included due to occasional patient dropouts from six months’ vaginal bromocriptine 
treatment, poor quality of extracted RNA and stringent inclusion criteria. As a consequence, 
it was challenging to draw potential conclusions from the study. 
Ø There was a lot of variability with both PRL and PRL-R expression and there is no clear 
evidence exhibiting reduced expression of the above markers after bromocriptine treatment. 
Hence, further validation will be needed on the above markers at the protein level, typically 
using immunohistochemistry or uterine fluid to evaluate PRL levels at baseline and after six 
months of treatment.  
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7. FUTURE DIRECTIONS 
For the future evaluation of early diagnostic markers towards the onset or development of 
EAOC, the biomarkers developed from Studies I and II should be validated. This can be 
achieved using archived samples from women diagnosed with ovarian endometriosis who later 
developed clear-cell or endometrioid subtypes of ovarian cancer and comparing the samples 
with a cohort of women (controls) who had ovarian endometriosis without developing ovarian 
cancer. 
One endometrioma SC+, Endo36, which was used in both Study I and Study II, showed an 
aberrant molecular profile with >95% CI compared to other samples. It expressed high levels 
of CSC markers CD44+ CD133+ (both by flow cytometry and immunofluorescence) and 
dedifferentiation markers (SOX2, NANOG). Furthermore, it exhibited chemo-resistance and 
higher 3D-spheroid invasion potential in the presence of paclitaxel treatment (Study I) and 
showed resistance to TGF-b-induced growth inhibition and upregulation of SDC-I. However, 
inhibition of SDC-1 during active TGF-b signalling suppressed its premalignant characteristics 
(Study II). Evaluation of such rare samples is needed to understand the molecular mechanisms 
involved in the early stages of cancer development. 
With respect to BRCA1 or BRCA2 mutations and ovarian cancer risk, the safety and efficacy 
of mifepristone after long-term treatment should be further studied and its outcomes correlated 
with breast and ovarian cell proliferation markers in vivo. Moreover, we should explore the 
molecular alterations that occur within adnexal sites (fallopian tubes, distal fimbriae, etc.) from 
women who underwent RRSO for preinvasive conditions such as serous tubal intraepithelial 
carcinoma and/or BRCA1 or BRCA2 mutation, to identify early biomarkers for high-grade 
ovarian cancers. 
Finally, it would be interesting to investigate the possibility of using bromocriptine within an 
intrauterine system among women with adenomyosis, in order to evaluate its safety and 
efficacy for sustained relief from disease symptoms. 
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